Silexion Therapeutics (SLXN) announced it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the company’s management will be presenting at the upcoming Cancer Advocacy Group of Louisiana NeauxCancer 2025 Conference being held March 27th-29th, 2025 at The Roosevelt New Orleans Hotel in New Orleans, LA. The newly completed strategic plan builds upon Silexion’s recent promising preclinical data and is designed to maximize SIL-204’s potential across multiple delivery approaches to address the challenges of KRAS-driven cancers. The Company plans to report further details on the expanded plan alongside its presentation at the conference.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLXN:
- Biotech Alert: Searches spiking for these stocks today
- Silexion Therapeutics price target lowered to $5 from $9 at Maxim
- Silexion Therapeutics Receives Buy Rating from Naz Rahman Following Promising SIL-204 Pre-Clinical Results
- 3 Penny Stocks to Watch Now, 3/6/25
- Silexion Therapeutics Reports Positive Data for SIL204